Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 210

1.

Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.

Ponomarenko DM, Klimova ID, Chapygina YA, Dvornichenko VV, Zhukova NV, Orlova RV, Manikhas GM, Zyryanov AV, Burkhanova LA, Badrtdinova II, Oshchepkov BN, Filippova EV, Orlov SV, Kolesnikov SI, Sufianov AA, Baum SR, Zaitzeva OY, Komissarov AB, Grudinin MP, Kiselev OI, Tsyb AF, Venanzi F, Shcherbinina V, Chursov A, Gabai VL, Shneider AM.

Oncotarget. 2017 Mar 25;8(32):53730-53739. doi: 10.18632/oncotarget.16574. eCollection 2017 Aug 8.

2.

[Adenosine A2A receptor as a drug target for treatment of sepsis].

Sivak KV, Vasin AV, Egorov VV, Tsevtkov VB, Kuzmich NN, Savina VA, Kiselev OI.

Mol Biol (Mosk). 2016 Mar-Apr;50(2):231-45. doi: 10.7868/S0026898416020233. Review. Russian.

3.

The influenza A virus NS genome segment displays lineage-specific patterns in predicted RNA secondary structure.

Vasin AV, Petrova AV, Egorov VV, Plotnikova MA, Klotchenko SA, Karpenko MN, Kiselev OI.

BMC Res Notes. 2016 May 20;9:279. doi: 10.1186/s13104-016-2083-6.

4.

[ANTIVIRAL ACTIVITY OF THE DIHYDROQUERCETIN DURING THE COXSACKIEVIRUS B4 REPLICATION IN VITRO].

Galochkina AV, Zarubaev VV, Kiselev OI, Babkin VA, Ostroukhova LA.

Vopr Virusol. 2016;61(1):27-31. Russian.

PMID:
27145597
5.

CHRONIC HEPATITIS WITH DOUBLE B/C INFECTION: VIROLOGICAL, CLINICAL, MORPHOLOGICAL CHARACTERISTICS.

Dudanova OP, Shubina ME, Belavina IA, Elpaeva EA, Pisareva MM, Grudinin MP, Kiselev OI.

Klin Med (Mosk). 2016;94(4):289-294.

PMID:
28957609
6.

Observation and Spectroscopy of New Proton-Unbound Isotopes ³⁰Ar and ²⁹Cl: An Interplay of Prompt Two-Proton and Sequential Decay.

Mukha I, Grigorenko LV, Xu X, Acosta L, Casarejos E, Ciemny AA, Dominik W, Duénas-Díaz J, Dunin V, Espino JM, Estradé A, Farinon F, Fomichev A, Geissel H, Golubkova TA, Gorshkov A, Janas Z, Kamiński G, Kiselev O, Knöbel R, Krupko S, Kuich M, Litvinov YA, Marquinez-Durán G, Martel I, Mazzocchi C, Nociforo C, Ordúz AK, Pfützner M, Pietri S, Pomorski M, Prochazka A, Rymzhanova S, Sánchez-Benítez AM, Scheidenberger C, Sharov P, Simon H, Sitar B, Slepnev R, Stanoiu M, Strmen P, Szarka I, Takechi M, Tanaka YK, Weick H, Winkler M, Winfield JS, Zhukov MV.

Phys Rev Lett. 2015 Nov 13;115(20):202501. doi: 10.1103/PhysRevLett.115.202501. Epub 2015 Nov 9.

PMID:
26613434
7.

Discovery of a new class of antiviral compounds: camphor imine derivatives.

Sokolova AS, Yarovaya OI, Shernyukov AV, Gatilov YV, Razumova YV, Zarubaev VV, Tretiak TS, Pokrovsky AG, Kiselev OI, Salakhutdinov NF.

Eur J Med Chem. 2015 Nov 13;105:263-73. doi: 10.1016/j.ejmech.2015.10.010. Epub 2015 Oct 22.

PMID:
26498572
8.

Interleukin-24 inhibits influenza A virus replication in vitro through induction of toll-like receptor 3 dependent apoptosis.

Weiss R, Laengle J, Sachet M, Shurygina AP, Kiselev O, Egorov A, Bergmann M.

Antiviral Res. 2015 Nov;123:93-104. doi: 10.1016/j.antiviral.2015.09.005. Epub 2015 Sep 11.

PMID:
26367324
9.

[Ebola hemorrhagic fever: Properties of the pathogen and development of vaccines and chemotherapeutic agents].

Kiselev OI, Vasin AV, Shevyryova MP, Deeva EG, Sivak KV, Egorov VV, Tsvetkov VB, Egorov AY, Romanovskaya-Romanko EA, Stepanova LA, Komissarov AB, Tsybalova LM, Ignatjev GM.

Mol Biol (Mosk). 2015 Jul-Aug;49(4):541-54. doi: 10.7868/S0026898415040072. Russian.

10.

Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.

Rudenko L, Kiseleva I, Stukova M, Erofeeva M, Naykhin A, Donina S, Larionova N, Pisareva M, Krivitskaya V, Flores J; Russian LAIV Trial Study Group.

Vaccine. 2015 Sep 22;33(39):5110-7. doi: 10.1016/j.vaccine.2015.08.019. Epub 2015 Aug 19.

PMID:
26296497
11.

[Comparison of the influenza epidemics in Russia caused by the pandemic virus A(H1N1)pdm09 within the period from 2009 to 2013].

Karpova LS, Sominina AA, Burtseva EI, Pelikh MY, Feodoritova EL, Popovtseva NM, Stolyarov TP, Kiselev OI.

Vopr Virusol. 2015;60(3):19-24. Russian.

PMID:
26281302
12.

A genetically adjuvanted influenza B virus vector increases immunogenicity and protective efficacy in mice.

Kittel C, Wressnigg N, Shurygina AP, Wolschek M, Stukova M, Romanovskaya-Romanko E, Romanova J, Kiselev O, Muster T, Egorov A.

Arch Virol. 2015 Oct;160(10):2525-34. doi: 10.1007/s00705-015-2525-9. Epub 2015 Jul 28.

PMID:
26215439
13.

Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.

Tsybalova LM, Stepanova LA, Kuprianov VV, Blokhina EA, Potapchuk MV, Korotkov AV, Gorshkov AN, Kasyanenko MA, Ravin NV, Kiselev OI.

Vaccine. 2015 Jun 26;33(29):3398-406. doi: 10.1016/j.vaccine.2015.04.073. Epub 2015 May 11.

PMID:
25976545
14.

[Clinical efficacy of arbidol (umifenovir) in the therapy of influenza in adults: preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR].

Kiselev OI, Maleev VV, Deeva EG, Leneva IA, Selkova EP, Osipova EA, Obukhov AA, Nadorov SA, Kulikova EV.

Ter Arkh. 2015;87(1):88-96. doi: 10.17116/terarkh201587188-96. Russian.

PMID:
25823275
15.

Glycyrrhizic acid derivatives as influenza A/H1N1 virus inhibitors.

Baltina LA, Zarubaev VV, Baltina LA, Orshanskaya IA, Fairushina AI, Kiselev OI, Yunusov MS.

Bioorg Med Chem Lett. 2015 Apr 15;25(8):1742-1746. doi: 10.1016/j.bmcl.2015.02.074. Epub 2015 Mar 7.

PMID:
25801933
16.

Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.

Stepanova LA, Kotlyarov RY, Kovaleva AA, Potapchuk MV, Korotkov AV, Sergeeva MV, Kasianenko MA, Kuprianov VV, Ravin NV, Tsybalova LM, Skryabin KG, Kiselev OI.

PLoS One. 2015 Mar 23;10(3):e0119520. doi: 10.1371/journal.pone.0119520. eCollection 2015.

17.

Identification of genetic determinants of influenza A virus resistance to adamantanes and neuraminidase inhibitors using biological microarray.

Heydarov RN, Fesenko EE, Shaskolskiy BL, Klotchenko SA, Vasin AV, Titov SV, Dementieva EI, Zasedatelev AS, Mikhailovich VM, Kiselev OI.

Dokl Biochem Biophys. 2015;460:4-8. doi: 10.1134/S1607672915010032. Epub 2015 Mar 13. No abstract available.

PMID:
25772979
18.

[The use of apoptosis inducers in the therapy of experimental influenza infection and preventing of chronic post-influenza lung damage].

Zarubaev VV, Tribulovich VG, Beliavskaia SV, Barlev NA, Kiselev OI.

Tsitologiia. 2014;56(3):241-7. Russian.

PMID:
25509421
19.

Novel derivatives of usnic acid effectively inhibiting reproduction of influenza A virus.

Shtro AA, Zarubaev VV, Luzina OA, Sokolov DN, Kiselev OI, Salakhutdinov NF.

Bioorg Med Chem. 2014 Dec 15;22(24):6826-36. doi: 10.1016/j.bmc.2014.10.033. Epub 2014 Oct 31.

PMID:
25464881
20.

Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.

Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.

Antiviral Res. 2015 Jan;113:4-10. doi: 10.1016/j.antiviral.2014.10.015. Epub 2014 Nov 12.

PMID:
25446335

Supplemental Content

Loading ...
Support Center